AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8363681
Drug: Labetalol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Labetalol (200 mg initial dose, repeat 100-200 mg at 2 hours)
Trial: 8363681
Drug: Nifedipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nifedipine (10 mg bite and swallow every hour up to 20 mg total)
Trial: 24844271
Drug: Liraglutide 1.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liraglutide 1.8 mg once daily for 24 weeks
Trial: 10655908
Drug: Ketamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine infusion (2.5 micrograms kg‐1 min‐1)
Trial: 8542050
Drug: benazepril/hydrochlorothiazide, 20/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril/hydrochlorothiazide, 20/25 mg
Trial: 8542050
Drug: benazepril, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: benazepril, 20 mg
Trial: 8542050
Drug: hydrochlorothiazide, 25
RxNorm normalized name: HydroCHLOROthiazide, 25 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide, 25 mg
Trial: 8263299
Drug: T.O.M. ointment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: T.O.M. ointment containing oestradiol; applied before each breastfeeding from the 2nd to the 6th or 7th day of life.
Trial: 8263299
Drug: Ointment without
RxNorm normalized name: threonine
DrugBank: Threonine (DB00156)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ointment without oestradiol (non-treated group); applied before each breastfeeding from the 2nd to the 6th or 7th day of life.
Trial: 3986167
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of 200 mg of progesterone
Trial: 3986167
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of 400 mg of progesterone
Trial: 3986167
Drug: Vaginal administration
RxNorm normalized name: Antiinflammatory products for vaginal administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal administration of 400 mg of progesterone (compared to placebo)
Trial: 31899564
Drug: Counseling +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Counseling + Nicotine Replacement Therapy (C + NRT)
Trial: 30115484
Drug: Intravenous remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous remifentanil PCA (40 μg bolus on demand with a 2 min lockout)
Trial: 30115484
Drug: Intramuscular pethidine
RxNorm normalized name: pethidine
DrugBank: Meperidine (DB00454)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intramuscular pethidine (100 mg every 4 h, up to 400 mg in 24 h)
Trial: 27537587
Drug: propofol/remifentanil/DEX with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol/remifentanil/DEX with loading dose (PRDw)
Trial: 27537587
Drug: propofol/remifentanil/DEX without
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol/remifentanil/DEX without loading dose (PRDo)
Trial: 27537587
Drug: propofol/remifentanil/Ringer solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol/remifentanil/Ringer solution (PRR)
Trial: 20434110
Drug: 0.03 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.03 mg/kg atracurium
Trial: 20434110
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg succinylcholine
Trial: 6338682
Drug: Postsynaptic alpha‐adrenoceptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postsynaptic alpha‐adrenoceptor blockade (prazosin, 2 mg orally)
Trial: 6338682
Drug: Combined postsynaptic
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined postsynaptic alpha‐ and non‐selective beta‐adrenoceptor blockade (labetalol, 200 mg orally)
Trial: 29268598
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline (15 mL)
Trial: 30041771
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) added to conventional treatment (aspirin 100mg/day with low molecular weight heparin)
Trial: 30041771
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment (aspirin 100mg/day with low molecular weight heparin)
Trial: 17080429
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (creatine monohydrate, coenzyme Q(10), and lipoic acid)
Trial: 9458917
Drug: 17 beta-estradiol
RxNorm normalized name: 17 beta-estradiol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17 beta-estradiol (transdermal patch, approximately 0.1 mg/day)
Trial: 9458917
Drug: Hypertonic saline
RxNorm normalized name: ENTSOL Hypertonic Saline Nasal Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypertonic saline infusion (3% NaCl)
Trial: 9156817
Drug: Dextran‐40 based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dextran‐40 based preservation solution (Dex‐PS)
Trial: 23768947
Drug: Existential Behavioural
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Existential Behavioural Therapy (EBT) with mindfulness training
Trial: 11242723
Drug: Benzocaine 20%
RxNorm normalized name: BENZOCAINE 20% GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzocaine 20% oral adhesive (Orabase-B)
Trial: 11242723
Drug: Benzocaine 20%
RxNorm normalized name: BENZOCAINE 20% GEL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzocaine 20% gel (Hurricaine)
Trial: 11242723
Drug: EMLA 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EMLA 5% oral adhesive (EMLA 5% cream in Orabase Plain)
Trial: 9140802
Drug: Nebivolol 10
RxNorm normalized name: nebivolol 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebivolol 10 mg once daily
Trial: 8274289
Drug: 0.0/0.2% isoquinoline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0/0.2% isoquinoline in white vaseline/lanette wax cream
Trial: 8274289
Drug: 0/10% tannic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0/10% tannic acid in lanette wax cream
Trial: 29176391
Drug: Average on-treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Average on-treatment SBP less than 142 mmHg (lowest tertile)
Trial: 20500867
Drug: Mandatory second
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mandatory second look surgery with CRS and HIPEC (intraperitoneal oxaliplatin with concurrent systemic 5-fluorouracil and leucovorin)
Trial: 16817817
Drug: Low-dose continuous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose continuous combined HRT (1 mg 17beta oestradiol and 0.5 mg norethisterone acetate)
Trial: 1628373
Drug: Single dose
RxNorm normalized name: Citrucel Single Dose Packets (Orange)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of 125 mg MPN
Trial: 1628373
Drug: Two doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two doses of 125 mg MPN
Trial: 6432200
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg naftidrofuryl, twice daily infusions
Trial: 6432200
Drug: 4% dextrose
RxNorm normalized name: Clinimix 8/14 Sulfite Free, Amino Acids 8% with 14% Dextrose (Clinimix Sulfite-Free) intravenous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% dextrose and saline infusion (control)
Trial: 29182791
Drug: Aprepitant 80
RxNorm normalized name: aprepitant 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 80 mg/day for 7 days plus standardized topical treatment (moderately strong steroid and moisturizer)
Trial: 29182791
Drug: Standardized topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standardized topical treatment alone (control group)
Trial: 24762381
Drug: Aqueous oxygen
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous oxygen peroxide (AOP) treatment
Trial: 22352336
Drug: Darunavir/ritonavir (DRV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Darunavir/ritonavir (DRV/r) 800/100 mg qd with emtricitabine/tenofovir 200/300 mg qd
Trial: 22352336
Drug: Atazanavir/ritonavir (ATV/r)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atazanavir/ritonavir (ATV/r) 300/100 mg qd with emtricitabine/tenofovir 200/300 mg qd
Trial: 12392804
Drug: Series of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Series of treatment-related videos
Trial: 7672157
Drug: 600 mg/d
RxNorm normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg/d of vitamin E
Trial: 2123160
Drug: Intranasal buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal buserelin acetate (n = 21)
Trial: 2123160
Drug: Subcutaneous buserelin
RxNorm normalized name: buserelin
DrugBank: Buserelin (DB06719)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous buserelin acetate (n = 19)
Trial: 464030
Drug: Myofeedback therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Myofeedback therapy
Trial: 30629728
Drug: Active intranasal
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active intranasal neurostimulation
Trial: 30629728
Drug: Sham control
RxNorm normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham control intranasal stimulation
Trial: 21255134
Drug: ximelagatran (higher
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ximelagatran (higher doses)
Trial: 21255134
Drug: ximelagatran (lower
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ximelagatran (lower and higher doses)
Trial: 21255134
Drug: aspirin alone
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: aspirin alone
Trial: 17696035
Drug: Low intensity
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low intensity laser therapy (LILT) with infrared laser (780 nm, 70 mW, 10 s, 89.7 J/cm2), applied twice a week for four weeks.
Trial: 2681451
Drug: Ketanserin 40
RxNorm normalized name: ketanserin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketanserin 40 mg b.i.d. for three months
Trial: 799991
Drug: Flurbiprofen 80
RxNorm normalized name: Flurbiprofen
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flurbiprofen 80 mg/day
Trial: 799991
Drug: Flurbiprofen or
RxNorm normalized name: flurbiprofen Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flurbiprofen or Ibuprofen
Trial: 31150356
Drug: Curcuminoid extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcuminoid extract 250 mg, four times a day on postoperative days 1-3
Trial: 29224209
Drug: 9-month course
RxNorm normalized name: moth bean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9-month course of daily isoniazid (9H)
Trial: 29224209
Drug: 12-week course
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 12-week course of weekly isoniazid and rifapentine (3HP)
Trial: 29224209
Drug: 3HP (12-week
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3HP (12-week course of weekly isoniazid and rifapentine)
Trial: 29224209
Drug: 9H (9-month
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 9H (9-month course of daily isoniazid)
Trial: 21125277
Drug: Aprepitant 125/80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 125/80 mg group (125 mg on day 1 and 80 mg on days 2-5) and dexamethasone (6 mg on day 1 and 4 mg on days 2 and 3)
Trial: 21125277
Drug: Aprepitant 40/25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aprepitant 40/25 mg group (40 mg on day 1 and 25 mg on days 2-5) and dexamethasone (8 mg on day 1 and 6 mg on days 2 and 3)
Trial: 19275475
Drug: Vidnar group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vidnar group (mobile narrative on a mobile phone during daily train trip)
Trial: 16951398
Drug: Neomycin (660
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neomycin (660 mg three times daily for three consecutive days, starting 2 days before chemotherapy)
Trial: 11460274
Drug: Tablet fluoride
RxNorm normalized name: sodium fluoride Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet fluoride (0.25 mg F daily)
Trial: 11460274
Drug: Liquid fluoride
RxNorm normalized name: sodium fluoride Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Liquid fluoride (0.25 mg F daily)
Trial: 3980272
Drug: Maintenance MeCCNU
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance MeCCNU + 5‐FU chemotherapy (21 patients)
Trial: 3980272
Drug: Overall treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall treatment (30 patients)
Trial: 27105046
Drug: Intensive therapy
RxNorm normalized name: Cortaid Intensive Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive therapy group (rosuvastatin 10 mg)
Trial: 27105046
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy group (rosuvastatin 2.5 mg)
Trial: 22337533
Drug: Postmenopausal hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Postmenopausal hormone therapy (ever vs. never)
Trial: 11174502
Drug: Prolonged antenatal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged antenatal betamethasone therapy (three or more sets of weekly injections given in 21.3% of cases, and > or =4 sets in 12.3% of cases)
Trial: 9886900
Drug: Pulse Wave
RxNorm normalized name: dulse extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulse Wave Analysis (PWA) for measuring Augmentation Index (AIx)
Trial: 23223772
Drug: Automated administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Automated administration of propofol and remifentanil
Trial: 21810630
Drug: Varenicline (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varenicline (1 mg daily dose)
Trial: 28543183
Drug: YH4808 (≥200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 (≥200 mg/d)
Trial: 28543183
Drug: YH4808 (twice-daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: YH4808 (twice-daily regimen)
Trial: 23261366
Drug: Imunoglukan P4H®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imunoglukan P4H® syrup (with pleuran-β-glucan from Pleurotus ostreatus and vitamin C)
Trial: 23261366
Drug: Imunoglukan P4H®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imunoglukan P4H® syrup
Trial: 19258951
Drug: Cisplatin/paclitaxel or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin/paclitaxel or carboplatin/paclitaxel (first-line chemotherapy)
Trial: 15462105
Drug: Celecoxib 200
RxNorm normalized name: celecoxib 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 200 mg daily for 4 weeks
Trial: 11737509
Drug: 0.12% chlorhexidine
RxNorm normalized name: CHLORHEXIDINE GLUCONATE 1.2 [iU] in 1 mL BUCCAL MOUTHWASH [0.12% Chlorhexidine Gluconate Oral Rinse]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.12% chlorhexidine aqueous solution (C)
Trial: 9240726
Drug: Hormone replacement
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hormone replacement therapy (HRT) or HRT and parathyroid hormone peptide 1-38
Trial: 3717020
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous heparin to maintain the whole blood clotting time between 15 and 20 minutes, and commenced warfarin therapy within 48 hours.
Trial: 3717020
Drug: Low-dose subcutaneous
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose subcutaneous heparin and warfarin therapy if the peak creatine kinase level was more than 1,000 U/liter.
Trial: 27560668
Drug: Internal conus
RxNorm normalized name: Blitum bonus-henricus pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internal conus design implants (ICI)
Trial: 27560668
Drug: External hex
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External hex design implants (EXI)
Trial: 27560668
Drug: Both ICI
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both ICI and EXI implants
Trial: 24354839
Drug: Text message
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text message reminders (5 weekly messages and 2 appointment reminders)
Trial: 18380893
Drug: Doxorubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin and docetaxel (ddAT) chemotherapy with tamoxifen
Trial: 18380893
Drug: Doxorubicin and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxorubicin and docetaxel (ddAT) chemotherapy without tamoxifen
Trial: 10713563
Drug: PEO/PBT 70/30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEO/PBT 70/30 (degradable implants)
Trial: 6361759
Drug: Chronic 4L
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic 4L plasma exchange therapy with albumin replacement
Trial: 6361759
Drug: Chronic 4L
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic 4L plasma exchange therapy with plasma replacement
Trial: 6361759
Drug: Chronic 4L
RxNorm normalized name: Chromic Chloride
DrugBank: Chromic chloride (DB09129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Chronic 4L plasma exchange therapy
Trial: 26662838
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 300 U/ml (Gla‐300)
Trial: 26662838
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine 100 U/ml (Gla‐100)
Trial: 24956862
Drug: Detoxifying and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Detoxifying and blood circulation activating treatment with extraction of polygonum cuspidatum and hawthorn, 1 pill po, bid (5.33 mg x kg(‐1) x d(‐1) polygonum cuspidatum extraction, 5.0 mg x kg(‐1) x d(‐1) hawthorn extraction)
Trial: 24956862
Drug: Lovastatin 20
RxNorm normalized name: lovastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 20 mg po, qd (0.33 mg x kg(‐1) x d(‐1))
Trial: 22326943
Drug: L-theanine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-theanine (100 mg)
Trial: 22326943
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of caffeine and L-theanine
Trial: 17030353
Drug: Platinum-based combination
RxNorm normalized name: platinum
DrugBank: Platinum (DB12257)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Platinum-based combination chemotherapy
Trial: 12092010
Drug: Chemotherapy regimens
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy regimens for gestational trophoblastic neoplasia
Trial: 19744533
Drug: Exposure to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exposure to pictures of fruits and vegetables (reading a picture book daily for two weeks)
Trial: 17550998
Drug: Low-dose testosterone
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose testosterone supplementation (100 mg im every 2 weeks for 26 weeks)
Trial: 11401641
Drug: latanoprost (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: latanoprost (50 microg/ml once daily)
Trial: 29282768
Drug: Paracetamol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol (3 g/day)
Trial: 29282768
Drug: Buprenorphine transdermal
RxNorm normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine transdermal system (max. 10 μg/h/7 days)
Trial: 27572001
Drug: Prolonged dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prolonged dual antiplatelet therapy (DAPT) for 24 months
Trial: 27572001
Drug: Short dual
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short dual antiplatelet therapy (DAPT) for ≤6 months
Trial: 18375893
Drug: Weekly paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly paclitaxel 80 mg/m2
Trial: 18375893
Drug: Every-3-weeks paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Every-3-weeks paclitaxel 175 mg/m2
Trial: 16361020
Drug: Standard swallowing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard swallowing therapy
Trial: 12873289
Drug: Soluble human
RxNorm normalized name: Recombinant soluble human CD4
DrugBank: Recombinant soluble human CD4 (DB17782)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soluble human insulin (HI)
Trial: 11077352
Drug: Ciprofloxacin 0.2%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin 0.2% solution (CIP)
Trial: 11077352
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of polymyxin B, neomycin, and hydrocortisone suspension (PNH)